Baseline immune state and T-cell clonal kinetics are associated with durable response to CAR-T therapy in large B-cell lymphoma
In this medfyle
Elevated baseline B-cell levels and a higher lymphocyte-to-monocyte ratio (ALC/AMC) were strongly associated with positive outcomes in LBCL patients treated with axi-cel. A predictive model combining B-cell proportion and ALC/AMC ratio demonstrated the ability to identify patients with significantly improved PFS. These findings suggest baseline immune profiles can both refine CAR-T product composition and optimize immune readiness, providing a practical tool to predict therapy response and enhance clinical decision-making.
About this Medfyle
©2025 Medfyle. All rights reserved.
This Medfyle is provided as a service to healthcare professionals. It has been created from content originally published in Blood, American Society of Hematology's official journal.
Original article: Maurer K, Grabski IN, Houot R, Gohil SH, Miura S, Redd R, Lyu H, Lu W, Arihara Y, Budka J, McDonough M, Ansuinelli M, Reynolds C, Jacene H, Li S, Livak KJ, Ritz J, Miles B, Mattie M, Neuberg DS, Irizarry RA, Armand P, Wu CJ, Jacobson C. Baseline immune state and T-cell clonal kinetics are associated with durable response to CAR-T therapy in large B-cell lymphoma. Blood. 2024 Dec 12;144(24):2490-2502.
